Table 1 Baseline description of the D2C cohort
Men | Women | |||
|---|---|---|---|---|
N | 12 650 | 47,3% | 14 092 | 52,7% |
Median follow-up time (years) | 3.54 | [0.3 - 5.8] | 3.79 | [0.2 - 5.8] |
Mean Age (years) | 62.6 | [40-79] | 65.2 | [40-79] |
Median BMI (kg/m2) | 29.7 | [16.3 - 44.9] | 31.0 | [16.2 - 44.9] |
Current smokers | 2934 | 23.2% | 1659 | 11.8% |
Year of enrolment in DMP | ||||
2003/2004 | 5 845 | 46.2% | 6 838 | 48.5% |
2005/2006 | 3 148 | 24.9% | 3 407 | 24.2% |
2007/2008 | 3 657 | 28.9% | 3 847 | 27.3% |
Anti-diabetic medication | ||||
No medication | 3 041 | 24.0% | 3 465 | 24.6% |
Metformin only | 4 580 | 36.2% | 5 064 | 35.9% |
Any other oral antidiabetic drug | 1 782 | 14.1% | 1 868 | 13.3% |
Human insulin (alone or with metformin) | 2 558 | 20.2% | 3 018 | 21.4% |
Insulin Analogues (alone or with insulin and/or metformin) | 690 | 5.5% | 677 | 4.8% |